Episode Details

Bionano Genomics completely rewired its business model to focus on selling high-margin consumables to a tiny fraction of power users, only to immediately run out of the raw materials needed to make them.

In ~10 minutes:

• How wafer delays caused a 10% drop in flowcell sales.

• Why just 60 customers now drive 56% of consumable revenue.

• The massive 47% Medicare reimbursement bump hitting in 2026.

• The ticking "going concern" clock tied to May 2026 debt.

Management has successfully slashed $100 million in OPEX, keeping costs completely flat as they fight for profitability. But with liquidity dipping to $29.6 million, the company is walking a tightrope between clearing their hardware backlog and surviving long enough to see the benefits of their new pricing windfall.

Company: Bionano Genomics, Inc. (BNGO) | Q4 FY2025

AI-assisted production. Feedback/ticker requests: https://x.com/EarnUnscripted.